Judo Bio is pioneering oligonucleotide medicines delivered to the kidney, opening the way for new genetic medicines for systemic and renal diseases. With its STRIKE (Selectively Targeting RNA Into KidnEy) platform, the company is using a proprietary approach to create ligand-RNA conjugate drugs designed for receptor-mediated update by specific kidney cell types, resulting in gene silencing of disease-modifying target genes.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/07/24 | $100,000,000 | Seed and Series A |
Alexandria Venture Investments Atlas Venture  Digitalis Ventures DROIA Ventures Euclidean Capital TCG The Column Group YK Bioventures | undisclosed |
